Pioglitazone Trial for Kidney Disease
Phase 4
28
about 8 years
35–70
2 sites in TX
Why this study is shown
What this study is about
This trial is testing whether a short-term treatment with pioglitazone can reduce sympathetic nerve activity in people with chronic kidney disease. The goal is to see if pioglitazone helps lower the risk of cardiovascular problems and death in these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Pioglitazone
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pioglitazone (Thiazolidinedione; improves insulin sensitivity by activating PPAR-gamma)
oral (Oral Tablet)
Renal